Our working hypothesis is that blood analytes associated with whole-body and liver metabolic health (e.g., FGF21 and one of its downstream effectors adiponectin), either singly or in combination, can be used as adjunct predictive tools for NAFLD status and liver fat changes in children. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.